NLS Pharmaceutics Announces Parkinson's Preclinical Results
Ticker: NCEL · Form: 6-K · Filed: Jun 27, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jun 27, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: preclinical-results, pharmaceuticals, shareholder-meeting
TL;DR
NLS Pharma's Parkinson's drug shows promise in early tests; shareholders approve all agenda items.
AI Summary
On June 27, 2024, NLS Pharmaceutics Ltd. announced promising preclinical results for its Parkinson's disease treatments via a press release. The company also held an ordinary shareholders' meeting on the same date where all agenda items were approved.
Why It Matters
Positive preclinical results could advance NLS Pharmaceutics' Parkinson's disease treatments, potentially impacting future therapeutic options for patients.
Risk Assessment
Risk Level: medium — Preclinical results are early-stage and do not guarantee future success or regulatory approval.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- June 27, 2024 (date) — Announcement and Meeting Date
- Parkinson's Disease (medical_condition) — Therapeutic Area
FAQ
What specific preclinical results were announced by NLS Pharmaceutics?
The filing states that NLS Pharmaceutics announced "promising preclinical results" for its Parkinson's disease treatments but does not provide specific details within this document.
What was the outcome of the ordinary shareholders' meeting held on June 27, 2024?
At the ordinary shareholders' meeting on June 27, 2024, a quorum was present, and shareholders approved all agenda items.
What is the primary purpose of this 6-K filing?
This 6-K filing is to report a press release issued by NLS Pharmaceutics Ltd. on June 27, 2024, regarding preclinical results for Parkinson's disease treatments, and to announce the proceedings of their shareholders' meeting.
Where is NLS Pharmaceutics Ltd. based?
NLS Pharmaceutics Ltd. is based in Zurich, Switzerland, with its principal executive offices located at The Circle 6, 8058 Zurich, Switzerland.
Does NLS Pharmaceutics file annual reports under Form 20-F or 40-F?
NLS Pharmaceutics Ltd. indicates that it files annual reports under cover of Form 20-F.
Filing Stats: 374 words · 1 min read · ~1 pages · Grade level 13.2 · Accepted 2024-06-27 16:54:14
Filing Documents
- ea0208624-6k_nlspharma.htm (6-K) — 12KB
- ea020862401ex99-1_nlspharma.htm (EX-99.1) — 13KB
- 0001213900-24-056712.txt ( ) — 26KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: June 27, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2